期刊
EUROPEAN JOURNAL OF OPHTHALMOLOGY
卷 27, 期 1, 页码 74-79出版社
SAGE PUBLICATIONS LTD
DOI: 10.5301/ejo.5000880
关键词
Aflibercept; Anti-VEGF; Neovascular age-related macular degeneration; Pigment epithelium detachment
资金
- Ministry of Health and Fondazione Roma
Purpose: To evaluate individualized intravitreal aflibercept regimens for treatment of neovascular age-related macular degeneration (nAMD)-related pigment epithelial detachment (PED). Methods: This prospective, multicenter, nonrandomized study included 32 eyes with nAMD-related PED, treated with ranibizumab for >= 6 months. All patients received intravitreal aflibercept (2 mg/0.05 mL) at baseline (no loading phase) and subsequently treated pro re nata with monthly follow-up for 12 months. Outcome measures included visual acuity, central retinal thickness (CRT), PED height and area, and neovascular network size. Results: At 12 months, aflibercept improved mean best-corrected visual acuity compared with baseline values (p>0.05); 50% of patients displayed complete resolution of intraretinal and/or subretinal fluid. Compared with baseline, significant decreases were observed for mean CRT and PED height (both p<0.01). Conclusions: Aflibercept appears to induce anatomical improvement for at least 12 months after conversion from ranibizumab in patients experiencing nAMD-related PED. Significant reductions in both mean PED height and CRT were observed, although these changes were not necessarily related to significantly improved visual acuity scores. However, larger patient cohorts are required to extend and validate our results, and increased study duration would allow exploration of the potential long-term benefits and challenges of prolonged aflibercept use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据